里瓦斯蒂格明对实验性试索米亚症的病变发生的影响
Letícia Farto de Rossi1, Bárbara Gonçalves2, Henrique Frediani2
1Health and Aging at the Famema, Marília Medical School, Marília, SP 17519-100, Brazil.
Parasitology international
|November 28, 2025
概括
抗胆酶药物里瓦斯蒂格明在查加斯病 (CD) 鼠标模型中降低了寄生病和死亡率. 这项研究表明,利瓦斯蒂格明可能调节胆固醇通路,为CD提供潜在的治疗选择.
科学领域:
- *免疫学和寄生虫学:专注于查加斯病发病的炎症机制.
- *药理学:研究抗胆酶药物的抗炎和治疗潜力.
背景情况:
- * 查加斯病 (CD) 治疗疗效有限.
- *抗胆酶药物具有潜在的抗炎性质.
- * 探索了胆固醇通路在疾病发病过程中的作用.
研究的目的:
- * 评估里瓦斯蒂格明对查加斯病的抗炎胆性通路的作用.
- * 评估rivastigmine对寄生病,死亡率,氧化应激和CD小鼠模型中的酶活性的影响.
主要方法:
- *120只瑞士小鼠被分为受感染和未受感染的群体,在感染后的30,60和180天接受或不接受里瓦斯蒂格明治疗.
- *评估的参数包括寄生病,组织病理学,谷氨酸 (GSH),降解铁的抗氧化能力 (FRAP),铁酸反应物质 (TBARS),丁胆酶 (BChE) 和乙胆酶 (AChE) 的活性.
- *进行了in silico分析,以了解里瓦斯蒂格明和乙胆酶 (AChE) 之间的相互作用.
主要成果:
- * 里瓦斯蒂格明治疗 (INF+RIV组) 在夏加斯病急性阶段显著降低了寄生病和死亡率.
- * 感染群体中增加的GSH水平表明了急性阶段的氧化损伤.
- *在60天的感染群体中,乙胆酶 (AChE) 活性降低,而在所有时间点的感染群体中,乙胆酶 (BChE) 活性增加.
结论:
- * 里瓦斯蒂格明在查加斯病中表现出对非神经元胆性通路的潜在调节作用.
- *该药物减少了感染急性阶段的寄生病和体内死亡率.
- * 需要进一步的研究,以充分阐明里瓦斯蒂格因在查加斯病中作用的机制.
相关概念视频
Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
American Trypanosomiasis
Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


